TY - JOUR
T1 - Acquired resistance to tyrosine kinase inhibitors in non-small cell lung cancers
T2 - The role of next-generation sequencing on endobronchial ultrasound-guided transbronchial needle aspiration samples
AU - Guerini-Rocco, Elena
AU - Passaro, Antonio
AU - Casadio, Chiara
AU - De Luca, Valeria Midolo
AU - Guarize, Juliana
AU - De Marinis, Filippo
AU - Vacirca, Davide
AU - Barberis, Massimo
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Context.-Molecular testing is essential for the diagnostic workup of patients with advanced non-small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound-guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular nextgeneration sequencing-based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor-resistant non-small cell lung cancers raises unique technical, biologic, and clinical challenges. Objective.-To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound-guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non-small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. Data Sources.-Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. Conclusions.-Next-generation sequencing analyses and the endobronchial ultrasound-guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor-resistant non-small cell lung cancers.
AB - Context.-Molecular testing is essential for the diagnostic workup of patients with advanced non-small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound-guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular nextgeneration sequencing-based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor-resistant non-small cell lung cancers raises unique technical, biologic, and clinical challenges. Objective.-To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound-guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non-small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. Data Sources.-Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. Conclusions.-Next-generation sequencing analyses and the endobronchial ultrasound-guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor-resistant non-small cell lung cancers.
UR - http://www.scopus.com/inward/record.url?scp=85044505747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044505747&partnerID=8YFLogxK
U2 - 10.5858/arpa.2017-0158-RA
DO - 10.5858/arpa.2017-0158-RA
M3 - Article
AN - SCOPUS:85044505747
VL - 142
SP - 465
EP - 473
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
SN - 0003-9985
IS - 4
ER -